{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.72","upperLimit":"7.10","value":"1.71"},{"comment":"only 3 DOR event observed","groupId":"OG001","lowerLimit":"0.03","upperLimit":"NA","value":"20.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Duration of response (DOR) by investigator assessment was analyzed and reported for both PCNSL and PTL patient populations.\n\nThis endpoint is further defined as the time from first response (CR or PR) to the date of initial objectively documented progression as determined using the IPCG Criteria for PCNSL and Lugano 2014 response evaluation for PTL, as determined by BICR, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG000","title":"PCNSL Cohort"},{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG001","title":"PTL Cohort"}],"paramType":"MEDIAN","populationDescription":"All responders PCNSL and PTL participants","reportingStatus":"POSTED","timeFrame":"Up to approximately 51 months","title":"Investigator-Assessed Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}